Cytosorbents Crp Total Liabilities
Cytosorbents Crp total liabilities. Based on the latest financial reports, Cytosorbents Crp (CTSO) has total liabilities worth $38.71 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Cytosorbents Crp to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cytosorbents Crp (2004–2025)
Total liabilities of Cytosorbents Crp from 2004 to 2025. This chart illustrates how Cytosorbents Crp's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Cytosorbents Crp to see how much of total assets are deployed in long-term investments.
Cytosorbents Crp Competitors by Total Liabilities
The table below lists competitors of Cytosorbents Crp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grand Foundry Limited
NSE:GFSTEELS
|
India | Rs188.21 Million |
|
Phapros Tbk PT
JK:PEHA
|
Indonesia | Rp1.01 Trillion |
|
Wintao Communications Co. Ltd
SHE:301139
|
China | CN¥1.42 Billion |
|
Little Green Pharma Ltd
AU:LGP
|
Australia | AU$11.59 Million |
|
Cerenome, Inc.
NASDAQ:CNSY
|
USA | $8.57 Million |
|
Bd Multimedia
PA:ALBDM
|
France | €2.94 Million |
|
Sparc Technologies Ltd
AU:SPN
|
Australia | AU$1.13 Million |
|
Managepay Systems Bhd
KLSE:0156
|
Malaysia | RM14.03 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Cytosorbents Crp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CTSO total assets.
Liquidity & Leverage Metrics
Cytosorbents Crp Total Liabilities Ratios Explained
Cytosorbents Crp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -51.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cytosorbents Crp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cytosorbents Crp (2004–2025)
The table below shows the annual total liabilities of Cytosorbents Crp from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $38.28 Million | +5.55% |
| 2024-12-31 | $36.26 Million | +20.94% |
| 2023-12-31 | $29.99 Million | +7.64% |
| 2022-12-31 | $27.86 Million | +3.40% |
| 2021-12-31 | $26.94 Million | +150.97% |
| 2020-12-31 | $10.73 Million | -55.21% |
| 2019-12-31 | $23.96 Million | +51.56% |
| 2018-12-31 | $15.81 Million | +14.25% |
| 2017-12-31 | $13.84 Million | +36.12% |
| 2016-12-31 | $10.17 Million | +234.06% |
| 2015-12-31 | $3.04 Million | -32.45% |
| 2014-12-31 | $4.51 Million | -75.39% |
| 2013-12-31 | $18.31 Million | +22.36% |
| 2012-12-31 | $14.96 Million | +729.43% |
| 2011-12-31 | $1.80 Million | -21.44% |
| 2010-12-31 | $2.30 Million | +136.57% |
| 2009-12-31 | $970.76K | -5.54% |
| 2008-12-31 | $1.03 Million | +13.32% |
| 2007-12-31 | $906.87K | -16.19% |
| 2006-12-31 | $1.08 Million | +961.13% |
| 2005-12-31 | $101.97K | +13.30% |
| 2004-12-31 | $90.00K | -- |
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and criti… Read more